Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Abstract
Purpose: To update the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer to improve the accuracy of HER2 testing and its utility as a predictive marker in invasive breast cancer. Methods: ASCO/CAP convened an Update Committee that included coauthors of the 2007 guideline to conduct a systematic literature review and update recommendations for optimal HER2 testing. Results: The Update Committee identified criteria and areas requiring clarification to improve the accuracy of HER2 testing by immunohistochemistry (IHC) or in situ hybridization (ISH). The guideline was reviewed and approved by both organizations. Recommendations: The Update Committee recommends that HER2 status (HER2 negative or positive) be determined in all patients with invasive (early stage or recurrence) breast cancer on the basis of one or more HER2 test results (negative, equivocal, or positive). Testing criteria define HER2-positive status when (on observing within an area of tumor that amounts to > 10% of contiguous and homogeneous tumor cells) there is evidence of protein overexpression (IHC) or gene amplification (HER2 copy number or HER2/CEP17 ratio by ISH based on counting at least 20 cells within the area). If results are equivocal (revised criteria), reflex testing should be performed using an alternative assay (IHC or ISH). Repeat testing should be considered if results seem discordant with other histopathologic findings. Laboratories should demonstrate high concordance with a validated HER2 test on a sufficiently large and representative set of specimens. Testing must be performed in a laboratory accredited by CAP or another accrediting entity. The Update Committee urges providers and health systems to cooperate to ensure the highest quality testing. This guideline was developed through a collaboration between the American Society of Clinical Oncology and the College of American Pathologists and has been published jointly by invitation and consent in both Journal of Clinical Oncology and the Archives of Pathology & Laboratory Medicine. Copyright © 2013 American Society of Clinical Oncology and College of American Pathologists. All rights reserved. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission by American Society of Clinical Oncology or College of American Pathologists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“Trastuzumab had previously been shown to improve progression-free survival and overall survival when combined with chemotherapy in the metastatic setting.(28) Since 2005, several of the first-generation adjuvant trials have been updated and have confirmed the disease-free and overall survival benefit offered by 1 year…”
BackgroundIntratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Unequal treatment: confronting racial and ethnic disparities in health care
(2003) · Choice Reviews Online · doi:10.5860/choice.40-5843 · Cited by 7,043
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Self-citationHammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Self-citationTrastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-18-asocco · Cited by 1,816
Self-citationSmith, I., Procter, M., Gelber, R. D., Guillaume, S., Feyereislova, A., Dowsett, M., Goldhirsch, A., Untch, M., Mariani, G., Baselga, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60028-2 · Cited by 1,507
Self-citation
Cited by
Items 101–124 of 124
Sheng, X., Wang, L., He, Z., Shi, Y., Luo, H., Han, W., Yao, X., Shi, B., Liu, J., Hu, C., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.22.02912 · Cited by 185
Castelló, A., Pollán, M., Buijsse, B., Ruiz, A., Casas, A. M., Baena-Cañada, J. M., Lope, V, Antolín, S., Ramos, M., Muñoz, M., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.434 · Cited by 182
Luque-Cabal, M., García-Teijido, P., Fernández-Pérez, Y., Sánchez-Lorenzo, L., & Palacio-Vázquez, I. (2016) · Clinical Medicine Insights: Oncology · doi:10.4137/cmo.s34537 · Cited by 179
Brown, D., Smeets, D., Székely, B., Larsimont, D., Szász, A. M., Adnet, P.-Y., Rothé, F., Rouas, G., Nagy, Z. I., Faragó, Z., et al. (2017) · Nature Communications · doi:10.1038/ncomms14944 · Cited by 178
Huang, Y., Zhu, T., Zhang, X., Li, W., Zheng, X., Cheng, M., Ji, F., Zhang, L., Yang, C., Wu, Z., et al. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101899 · Cited by 175
Noonan, S. A., Berry, L., Lu, X., Gao, D., Barón, A. E., Chesnut, P., Sheren, J., Aisner, D. L., Merrick, D., Doebele, R. C., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.033 · Cited by 173
Graziano, V., Grassadonia, A., Iezzi, L., Vici, P., Pizzuti, L., Barba, M., Quinzii, A., Camplese, A., Di Marino, P., Peri, M., et al. (2019) · The Breast · doi:10.1016/j.breast.2018.12.014 · Cited by 173
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients
Chen, L., Yang, L., Yao, L., Kuang, X.-Y., Zuo, W.-J., Li, S., Qiao, F., Liu, Y.-R., Cao, Z.-G., Zhou, S.-L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03867-9 · Cited by 169
Tumor-Associated Macrophages as Potential Prognostic Biomarkers of Invasive Breast Cancer
Jeong, H., Hwang, I., Kang, S. H., Shin, H. C., & Kwon, S. Y. (2019) · Journal of Breast Cancer · doi:10.4048/jbc.2019.22.e5 · Cited by 169
“HER2 expression was also scored according to the ASCO/CAP guidelines [18], which include 4 scores ranging from 0 to 3: no staining or incomplete, faint/barely perceptible membrane staining in ≤10% of invasive tumor cells (score 0); incomplete, faint/barely perceptible membrane staining in >10% of invasive tumor cells…”
MethodBiomarker validation and testing
Hayes, D. F. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2014.10.004 · Cited by 167
Self-citationAndreev, J., Thambi, N., Perez Bay, A. E., Delfino, F., Martin, J., Kelly, M. P., Kirshner, J. R., Rafique, A., Kunz, A., Nittoli, T., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0658 · Cited by 166
“The efficacy of T-DM1 has been demonstrated only in patients with HER2 overexpression defined as IHC3þ (7) or FISH amplification ratio 2, which is only about half of metastatic breast cancer patients with detectable IHC HER2 expression (8, 9).”
BackgroundBiological determinants of PSMA expression, regulation and heterogeneity in prostate cancer
Bakht, M. K., & Beltran, H. (2025) · Nature Reviews Urology · doi:10.1038/s41585-024-00900-z · Cited by 158
“At the protein level, no universally accepted immunohistochemistry (IHC) scoring system has been established for PSMA, unlike the 0–3+ scale employed for HER2 in breast cancer 72 .”
Jhaveri, K. L., Wang, X. V., Makker, V., Luoh, S.-W., Mitchell, E. P., Zwiebel, J. A., Sharon, E., Gray, R. J., Li, S., McShane, L. M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz291 · Cited by 151
Self-citationRaghav, K., Loree, J. M., Morris, J. S., Overman, M. J., Yu, R., Meric-Bernstam, F., Menter, D., Korphaisarn, K., Kee, B., Muranyi, A., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00226 · Cited by 132
Wang, Y. “., Reder, N. P., Kang, S., Glaser, A. K., Yang, Q., Wall, M. A., Javid, S. H., Dintzis, S. M., & Liu, J. T. C. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0709 · Cited by 104
Gass, P., Lux, M. P., Rauh, C., Hein, A., Bani, M. R., Fiessler, C., Hartmann, A., Häberle, L., Pretscher, J., Erber, R., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4925-1 · Cited by 83
Zhang, G., Wang, Y., Chen, B., Guo, L., Cao, L., Ren, C., Wen, L., Li, K., Jia, M., Li, C., et al. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.04.23 · Cited by 66
Resting heart rate as a prognostic factor for mortality in patients with breast cancer
Lee, D. H., Park, S., Lim, S. M., Lee, M. K., Giovannucci, E. L., Kim, J. H., Kim, S. I., & Jeon, J. Y. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3938-1 · Cited by 58
Chen, M., Huang, R., Chen, R., Pan, F., Shen, X., Li, H., Rong, Q., An, X., Xue, C., & Shi, Y. (2024) · The Oncologist · doi:10.1093/oncolo/oyae055 · Cited by 49
Iwata, H., Inoue, K., Kaneko, K., Ito, Y., Tsugawa, K., Hasegawa, A., Nakagawa, S., Kuratomi, H., & Tamura, K. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz135 · Cited by 46
Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes
Chun, Y. S., Mizuno, T., Cloyd, J. M., Ha, M. J., Omichi, K., Tzeng, C.-W. D., Aloia, T. A., Ueno, N. T., Kuerer, H. M., Barcenas, C. H., et al. (2020) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2020.03.214 · Cited by 32
Schlienger, S., Campbell, S., Pasquin, S., Gaboury, L., & Claing, A. (2016) · Oncotarget · doi:10.18632/oncotarget.7515 · Cited by 26
“The product of the quantity and the staining intensity scores represents the total IHC score that ranges from 0 to 12 [42, 43].”
BackgroundYap, Y.-S., Leong, M. C., Chua, Y. W., Loh, K. W. J., Lee, G. E., Lim, E. H., Dent, R., Ng, R. C. H., Lim, J. H.-C., Singh, G., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0221305 · Cited by 23
“The determination of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status by immunohistochemistry in this study was based on the latest recommendations by the American Society of Clinical Oncology and the College of American Pathologists.”
MethodSenolytic effect of high intensity interval exercise on human skeletal muscle
Jean, W.-H., Hsieh, Y.-W., Lai, L.-F., Dewi, L., Liao, Y.-C., Ye, M., Yu, S.-H., Kao, C.-L., Huang, C.-Y., & Kuo, C.-H. (2023) · Aging · doi:10.18632/aging.204511 · Cited by 18
Metadata
- Authors
- Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., Hanna, W., Jenkins, R. B., Mangu, P. B., Paik, S., Perez, E. A., Press, M. F., Spears, P. A., Vance, G. H., Viale, G., & Hayes, D. F.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-11-01
- Volume
- 31
- Issue
- 31
- Pages
- 3997-4013
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2101979288
- Cited by
- 4,030
- References
- 87
- FWCI
- 145.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.